2022 Fall PCE Oncology Conference Series

For oncology NPs, PAs, and nurses

Now Available:

  • Downloadable Slidesets: Access the slides from the live meetings to use and share in your noncommercial presentations to colleagues or patients.
  • Expert Commentaries
  • Downloadable Resource: "Key Takeaways From the Patient Education Forum"
  • On-demand Webcasts

 

Share

Program Content

Exploring the Latest Advances in Basal Cell Carcinoma
Exploring the Latest Advances in Basal Cell Carcinoma
Congratulations: You achieved a completion on 04/09/2022
View Activity
Pt Education BCC Tx Tox
What Patients With BCC Need to Know About Therapy-Related Toxicities
Congratulations: You achieved a completion on 04/09/2022
View Activity
Exploring the Latest Advances in Basal Cell Carcinoma
Exploring the Latest Advances in Basal Cell Carcinoma
Congratulations: You achieved a completion on 04/09/2022
View Activity
Living Longer With HER2+ Breast Cancer: Sequencing Newer Therapies to Improve Survival
Living Longer With HER2+ Breast Cancer: Sequencing Newer Therapies to Improve Survival
Congratulations: You achieved a completion on 04/09/2022
View Activity
Toxicities With HER2 Therapies
Managing Diarrhea and Interstitial Lung Disease With Newer HER2-Directed Therapies
Congratulations: You achieved a completion on 04/09/2022
View Activity
Breast Cancer
Living Longer With HER2+ Breast Cancer: Sequencing Newer Therapies to Improve Survival
Congratulations: You achieved a completion on 04/09/2022
View Activity
Applying the Expanding Range of Options for Advanced Gastric Cancer
Applying the Expanding Range of Options for Advanced Gastric Cancer
Congratulations: You achieved a completion on 04/09/2022
View Activity
Gastric Cancer Tx
How I Use Immunotherapy to Treat Metastatic HER2-Negative Gastric Cancer
Congratulations: You achieved a completion on 04/09/2022
View Activity
Applying the Expanding Range of Options for Advanced Gastric Cancer
Applying the Expanding Range of Options for Advanced Gastric Cancer
Congratulations: You achieved a completion on 04/09/2022
View Activity
PARP Inhibitors as Precision Medicine in Metastatic Prostate Cancer
PARP Inhibitors as Precision Medicine in Metastatic Prostate Cancer
Congratulations: You achieved a completion on 04/09/2022
View Activity
Prostate Ca Side Effects
How I Manage Bothersome and Distressing Side Effects from PARP Inhibitors and ADT in Patients with Prostate Cancer
Congratulations: You achieved a completion on 04/09/2022
View Activity
Treating Gynecologic Cancers: Current Approaches to Patient Care
Treating Gynecologic Cancers: Current Approaches to Patient Care
Congratulations: You achieved a completion on 04/09/2022
View Activity
Gyn Cancer: Education and Support
How I Practice: Education and Support for Caregivers and Patients With Gynecologic Cancer
Congratulations: You achieved a completion on 04/09/2022
View Activity
Advances in Gynecologic Cancers
Treating Gynecologic Cancers: Current Approaches to Patient Care
Congratulations: You achieved a completion on 04/09/2022
View Activity
Advancing Care for HR+/HER2- Breast Cancer: Managing Patients With CDK4/6 Inhibitors
Advancing Care for HR+/HER2- Breast Cancer: Managing Patients With CDK4/6 Inhibitors
Congratulations: You achieved a completion on 04/09/2022
View Activity
SDM in Newly Diagnosed MBC
Choosing a CDK4/6 Inhibitor in the Frontline Setting for HR+/HER2- Metastatic Breast Cancer: Highlighting the Importance of Shared Decision-Making
Congratulations: You achieved a completion on 04/09/2022
View Activity
Advancing Care for HR+/HER2- Breast Cancer
Advancing Care for HR+/HER2- Breast Cancer: Managing Patients With CDK4/6 Inhibitors
Congratulations: You achieved a completion on 04/09/2022
View Activity
Advances in Immune Checkpoint Inhibitor Therapy for Patients with Non-Small-Cell Lung Cancer: Applications to Clinical Practice
Advances in Immune Checkpoint Inhibitor Therapy for Patients with Non-Small-Cell Lung Cancer: Applications to Clinical Practice
Congratulations: You achieved a completion on 04/09/2022
View Activity
irAE Recognition
Importance of Early Recognition and Management of Immune-Related Adverse Events to Optimize Outcomes With Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer and Other Malignancies
Congratulations: You achieved a completion on 04/09/2022
View Activity
Advances in Immune Checkpoint Inhibitor Therapy
Advances in Immune Checkpoint Inhibitor Therapy for Patients with Non-Small-Cell Lung Cancer: Applications to Clinical Practice
Congratulations: You achieved a completion on 04/09/2022
View Activity
  • PARP Inhibitors
    PARP Inhibitors as Precision Medicine in Metastatic Prostate Cancer
    Multimedia
    Congratulations: You achieved a completion on 04/09/2022
    View Activity
  • Patient and Provider
    Patient and Provider: What We Can Learn From Each Other
    Multimedia
    Congratulations: You achieved a completion on 04/09/2022
    View Activity

Faculty

cover img faculity

Maria Avila-Wallace, NP

Nurse Practitioner
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Massachusetts General Hospital
Boston, Massachusetts

cover img faculity

Jennifer Bridgeforth-Jackson,

Adjunct Professor
School of Business
National Louis University
Chicago, Illinois

cover img faculity

Marianne Davies, DNP, ACNP

Associate Professor
Yale School of Nursing
Senior Advanced Practice Nurse
Smilow Cancer Hospital at Yale New Haven
Yale Comprehensive Cancer Center
New Haven, Connecticut

cover img faculity

Jeremy M. Force, DO

Assistant Professor
Department of Medicine
Division of Medical Oncology
Breast Oncology Program
Duke University
Durham, North Carolina

cover img faculity

Rachel Frankenthal, PA-C, MPH

Physician Assistant
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of California, Los Angeles
Los Angeles, California

cover img faculity

Kathleen Madden, MSN

Nurse Practitioner
Melanoma Program
Perlmutter Cancer Center
NYU Langone Health
New York, New York

cover img faculity

Steven Maron, MD

Assistant Attending Physician
Gastrointestinal Medical Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

cover img faculity

David Scott Miller, MD, FACOG, FACS

Amy and Vernon E. Faulconer Distinguished Chair in Medical Science
Director and Dallas Foundation Chair in Gynecologic Oncology
Professor of Obstetrics & Gynecology
Fred F. Florence Bioinformation Center
University of Texas Southwestern Medical Center
Medical Director of Gynecologic Oncology
Chair,
Cancer Committee
Parkland Health & Hospital System
Dallas, Texas

cover img faculity

Caitlin Musick,

Video Producer
Los Angeles, California

cover img faculity

Rita Nanda, MD

Associate Professor of Medicine
Department of Medicine
Director, Breast Oncology
University of Chicago
Chicago, Illinois

cover img faculity

Kristi Kay Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

cover img faculity

Anna C. Pavlick, MD, MBA

Professor of Medicine and Dermatology
Department of Medical Oncology
Director
Melanoma and Cutaneous Oncology Program
Sandra and Edward Meyer Cancer Center
Weill Cornell Medicine
New York, New York

cover img faculity

Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN

Nurse Practitioner
Department of Urology
University of Virginia
Charlottesville, Virginia

cover img faculity

Sarah Traverso, MMS, PA-C

Physician Assistant
Division of Genitourinary Oncology
Northwestern Medicine
Chicago, Illinois

cover img faculity

Beth Sandy, MSN, CRNP

Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Bristol-Myers Squibb

Genmab

Janssen administered by Scientific Affairs

Janssen Biotech, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.

Lilly

Merck

Merck Sharp & Dohme Corp

Regeneron Pharmaceuticals, Inc

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme

Sanofi

Seagen

Seagen and Genmab

Seagen Inc.